Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

Pfizer

Status and phase

Completed

Phase 1

Conditions

Psoriasis

Treatments

Drug: Betamethasone

Drug: Calcipotriene/calcipotriol

Drug: PF-06763809

Other: Vehicle

Study type

Interventional

Funder types

Industry

Identifiers

NCT03469336

C3561001

2017-002684-18 (EudraCT Number)

Details and patient eligibility

About

The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers. Each subjects will receive three different topical doses of PF 06763809, PF 06763809 vehicle, and two active comparators. These will be applied to six different treatment fields for 18 days. The total duration of participation in the study will be approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval from Screening to the Follow up phone call visit.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas
Target lesion(s) should be on the trunk or extremities (excluding palms/soles).

Exclusion criteria

History of skin sensitivity to topical prescription or non prescription products such as creams, lotions and cosmetics
Psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, and pustular psoriasis
Treatment with any biologics within 3 months prior to Day 1 of the study and during the study